Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure

Status Completed

Clinical Trial Summary

The rapidly spreading coronavirus Covid-19 pandemic is a major concern worldwide and Italy is at the forefront of this emergency. At the present moment, the effects on the offspring of Covid-19 disease in pregnant women and/or the indirect effect of COVID-19-related prenatal maternal stress are poorly understood. Epigenetic mechanisms - and especially DNA methylation - are involved in the embedding of prenatal exposures to large-scale disasters into the epigenome and phenotypic outcomes of the offspring. Specific target genes include SLC6A4, NR3C1, OXTR, BDNF, and FKBP5. The central hypothesis of this project is that the exposure to the COVID-19-related prenatal maternal stress may affect infants' outcomes from birth to 12 months partially through increased methylation of target genes involved in stress regulation. The main goal is to investigate the association between Covid-19 disease in pregnancy or COVID-19-related PMS in women pregnant during the first 9 months of the year 2020 and the emotional, social, and cognitive developmental outcomes in their infants from birth to 12 months. Additionally, the role of target genes methylation in mediating this association will be investigated. Mothers and their infants will be enrolled from the delivery units of eleven neonatal facilities located in Northern Italy's COVID-19 contagion hotspot. One group will be enrolled from April to October 2020 (COVID-Exposure Pregnancy, CEP), a second group will be enrolled from April to October 2021 (Non-Exposure Pregnancy, NEP). Moreover, the CEP group will include mothers positive or exposed to COVID-19-related MPS during different trimesters of pregnancy, allowing within-group comparisons on developmentally sensitive time windows. Within 48 hours from baby delivery, saliva samples will be obtained from CEP and NEP newborns, immediately stored at -20°C and analyzed for epigenetic analyses using Next-Generation Sequencing. At 3 and 6 months, mothers will be asked to fill-in validated and reliable questionnaires on the emotional and social-behavioral development of their infants. At 12 months, infants' stress regulation and maternal sensitivity will be evaluated through video recording of mother-infant interactions. This study will provide unprecedented relevant insights on the biochemical mechanisms underlying the impact of Covid-19 disease and the related PMS on human offspring's developmental outcomes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04540029
Study type	Observational
Source	IRCCS National Neurological Institute "C. Mondino" Foundation
Contact
Status	Completed
Phase
Start date	May 6, 2020
Completion date	May 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05419167` - STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic	Phase 1
Active, not recruiting	`NCT04713150` - HEALthy Brain and Child Development Study - COVID-19 Supplement
Completed	`NCT04100577` - Today Not Tomorrow Pregnancy and Infant Support Program (TNT- PISP)	N/A
Recruiting	`NCT04154423` - Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study	N/A
Recruiting	`NCT04993742` - Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes	N/A
Suspended	`NCT05087329` - Mindfulness Practice in Pregnancy as an Intervention to Decrease Prenatal Stress During the COVID-19 Pandemic	N/A
Completed	`NCT05824208` - PRENAYOGA: Exploratory Feasibility Study of Bi-weekly Pregnancy Yoga-based Sessions for Ethnic Minority Women	N/A
Terminated	`NCT03809572` - Mindfulness Based Cognitive Therapy (MBCT) During Pregnancy	N/A
Active, not recruiting	`NCT04718220` - Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19	N/A
Completed	`NCT03809598` - Roo Study on Mom and Baby Well-Being	N/A
Completed	`NCT04293380` - Amniotic Fluid Ischemia Modified Albumin as a Novel e Prenatal Diagnostic Marker for Down Syndrome	N/A
Completed	`NCT04267211` - Prenatal Consult With Illustrated Literature	N/A
Active, not recruiting	`NCT04829864` - Supporting the Transition to and Engagement in Parenthood	Phase 1/Phase 2
Active, not recruiting	`NCT03028857` - Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal	Phase 1
Recruiting	`NCT03404141` - Stress Reduction Therapy for Pregnant Women	N/A
Completed	`NCT03615261` - Wellness For 2: A Feasibility and Acceptability Pilot	N/A
Completed	`NCT04427410` - The Relationship Between Oxytocin Level and Postpartum Depression
Active, not recruiting	`NCT05052281` - Promoting Healthy Brain Development: Wellness for 2 Study	N/A
Not yet recruiting	`NCT05745896` - A Telemedicine Prenatal Care Model on Low Risk Pregnants: The m@Mae-e Study	N/A
Recruiting	`NCT03970057` - MoodUP in Improving Psychological Outcomes Among Perinatal Women	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure — MOM-COPE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms